<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36920401</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6084</ISSN><JournalIssue CitedMedium="Internet"><Volume>159</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA dermatology</Title><ISOAbbreviation>JAMA Dermatol</ISOAbbreviation></Journal><ArticleTitle>Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>560</StartPage><EndPage>563</EndPage><MedlinePgn>560-563</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamadermatol.2023.0175</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Melendez</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Dustin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Dermatology, University of Vermont Medical Center, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaChance</LastName><ForeName>Avery</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahriari</LastName><ForeName>Neda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vleugels</LastName><ForeName>Ruth Ann</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Dermatol</MedlineTA><NlmUniqueID>101589530</NlmUniqueID><ISSNLinking>2168-6068</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>38RL9AE51Q</RegistryNumber><NameOfSubstance UI="C582345">anifrolumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008179" MajorTopicYN="Y">Lupus Erythematosus, Discoid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This case series examines the efficacy of anifrolumab as a therapeutic option for patients with lupus erythematosus.</AbstractText></OtherAbstract><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr LaChance reported grants from Pfizer outside the submitted work. Dr Vleugels reported grants from Pfizer PI outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36920401</ArticleId><ArticleId IdType="pmc">PMC10018404</ArticleId><ArticleId IdType="doi">10.1001/jamadermatol.2023.0175</ArticleId><ArticleId IdType="pii">2802155</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wahie S, Daly AK, Cordell HJ, et al. . Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011;131(10):1981-1986. doi:10.1038/jid.2011.167</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2011.167</ArticleId><ArticleId IdType="pubmed">21734714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprow G, Dan J, Merola JF, Werth VP. Emerging therapies in cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:968323. doi:10.3389/fmed.2022.968323</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.968323</ArticleId><ArticleId IdType="pmc">PMC9313535</ArticleId><ArticleId IdType="pubmed">35899214</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, et al. ; TULIP-2 Trial Investigators . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi:10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum FR, Sampath AJ, Foulke GT. Anifrolumab for treatment of refractory cutaneous lupus erythematosus. Clin Exp Dermatol. 2022;47(11):1998-2001. doi:10.1111/ced.15335</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ced.15335</ArticleId><ArticleId IdType="pubmed">35844070</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23(2):113-121. doi:10.1016/j.smim.2011.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2011.01.009</ArticleId><ArticleId IdType="pubmed">21292501</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Moghadam-Kia S, LoMonico J, et al. . Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203-208. doi:10.1001/archdermatol.2010.435</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archdermatol.2010.435</ArticleId><ArticleId IdType="pmc">PMC3282059</ArticleId><ArticleId IdType="pubmed">21339447</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>